Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | F12 | P00748 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1800839 | 0.80 | CDK5 (0.42) | MMP12MAPTKDM4ENPC1GLA | |
| SCHEMBL1021282 | 0.80 | MAPT (0.39) | MMP12MAPTKDM4ENPC1GLA | |
| SCHEMBL193008 | 0.77 | MAPT (0.37) | MMP12MAPTKDM4ENPC1GLA | |
| SCHEMBL4838743 | 0.77 | MAPT (0.37) | MMP12MAPTKDM4ENPC1GLA | |
| SCHEMBL28888432 | 0.73 | MMP12 (0.45) | MMP12MAPTKDM4EKMT2ABACE1 | |
| SCHEMBL1747899 | 0.65 | KDM4A (0.37) | MMP12MAPTKDM4EGLANOS3 | |
| SCHEMBL28391879 | 0.65 | ALDH1A1 (0.34) | MMP12MAPTKDM4ENPC1GLA | |
| SCHEMBL4872325 | 0.65 | CDK5 (0.41) | MMP12MAPTKDM4ENPC1GLA | |
| Hydrochloric Acid SCHEMBL3353320 | 0.64 | KDM4A (0.36) | MMP12MAPTKDM4ENOS3NOS2 | |
| SCHEMBL60386 | 0.64 | KDM4A (0.33) | NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390890-B2 | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2008-06-24 | — | — | US | disclosed |
| CN-100393722-C | Inhibitors of nucleoside metabolism | EINSTEIN COLL MED (US) | 2008-06-11 | — | — | CN | disclosed |
| US-20070197561-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007069924-A1 | DEAZAPURINE ANALOGS OF 4'-AZA-L-NUCLEOSIDES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2007-06-21 | — | — | WO | disclosed |
| US-7211653-B2 | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2007-05-01 | — | — | US | disclosed |
| CN-1757646-A | Inhibitors of nucleoside metabolism | EINSTEIN COLL MED (US) | 2006-04-12 | — | — | CN | disclosed |
| CN-1220695-C | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN MEDICAL COLLAG (US) | 2005-09-28 | — | — | CN | disclosed |
| EP-1023308-B1 | INHIBITORS OF NUCLEOSIDE METABOLISM | EINSTEIN COLL MED (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20050026936-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| US-6803455-B2 | PYRROLO(3,2-D)PYRIMIDIN-7-YL)-1,4-IMINO-D-RIBITOL DERIVATIVES; FOR SUPPRESSION OF T-CELL FUNCTION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2004-10-12 | — | — | US | disclosed |
| US-20030096830-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| US-6492347-B2 | TREATMENT AND/OR PROPHYLAXIS OF INFECTION CAUSED BY PROTOZOAN PARASITE BY ADMINISTERING COMPOUND TO INHIBIT PURINE NUCLEOSIDE HYDROLASE, PURINE NUCLEOSIDE PHOSPHORYLASE, AND/OR PURINE PHOSPHORIBOSYL TRANSFERASE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2002-12-10 | — | — | US | disclosed |
| US-20020061898-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| US-6228847-B1 | ADMINISTERING PYRROLO(3,2-D)PYRIMIDINE DERIVATIVES AS PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2001-05-08 | — | — | US | disclosed |
| CN-1279686-A | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLAGE OF MED (US) | 2001-01-10 | — | — | CN | disclosed |
| US-6066722-A | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| US-5985848-A | EFFECTIVE INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE AND/OR NUCLEOSIDE HYDROLASES; TREATMENT AND/OR PROPHYLAXIS OF A PROTOZOAN INFECTION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1999-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026936-A1 | Inhibitors of nucleoside metabolism | CFH, CBR3, SLCO2B1 | MMP12 4855/4885MAPT 2371/4885KDM4E 3165/4885 |
| US-20020061898-A1 | Inhibitors of nucleoside metabolism | PNP, APRT, NUDT14 | MMP12 2934/4885MAPT 134/4885KDM4E 2205/4885 |
| US-20070197561-A1 | Inhibitors of nucleoside metabolism | CFH, CBR3, SLCO2B1 | MMP12 4855/4885MAPT 2371/4885KDM4E 3165/4885 |
| US-20030096830-A1 | Inhibitors of nucleoside metabolism | CFH, NADK, UGT1A3 | MMP12 4824/4885MAPT 1964/4885KDM4E 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.